From the 4c released 31/07/17, Couldn't be bothered going further back, in the words of another poster .... enough said...
*Mesoblast is in advanced negotiations with selected pharmaceutical companies with respect to potential partnering of certain Tier 1 product candidates. If Mesoblast enters into a binding transaction in the next quarter, Mesoblast expects that one effect of the transaction is that its cash reserves are likely to increase. Mesoblast does not make any representation or give any assurance that such a binding transaction will be concluded.
In addition, Mesoblast expects its cash reserves to increase in the next quarter as we expect to receive the following income: ®
- royalty income earned on sales of TEMCELL HS Inj. in Japan, and
- interest income.
Mesoblast has established an equity facility for up to A$120 million/US$90 million over the next two years, to be used at its discretion to provide additional funds as required.
MSB Price at posting:
$1.47 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)